Esperion Therapeutics Stock News

Esperion (ESPR) reports mixed first-quarter 2023 results, wherein earnings miss and revenues beat estimates. The stock of the company surges 5% on Tuesday.

Esperion Therapeutics (ESPR) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to loss of $0.93 per share a year ago.

Investors are attracted to penny stocks for their potential to provide exponential gains. It is very common to find such companies trading for fractions of their target price.

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Short squeeze penny stocks for your watch list. The post Penny Stocks To Buy Now?

An SEC filing by Esperion (ESPR) reveals that partner Daiichi Sankyo disagrees with the company's assessment that cardiovascular outcome CLEAR study data would support milestone payments.

The stock price of Esperion Therapeutics Inc (NASDAQ: ESPR) plummeted by 54.27% in the most recent trading session. This is why.

Esperion Therapeutics (NASDAQ: ESPR ) stock is taking a beating on Thursday as the company comes into conflict with Daiichi Sankyo Europe . The problem between these two companies has to do with miles

Shares of Esperion Therapeutics Inc. ESPR plunged about 56% in premarket trading on Thursday, the day after the company told investors that there is a dispute about a million milestone payment for its

Shares of Esperion Therapeutics (ESPR) fell last week as the company's cardiovascular outcome CLEAR study results failed to meet investor expectations.

At least two biotech stocks are seeing increased scrutiny in the options pits, with BridgeBio Pharma  Inc (NASDAQ:BBIO) and Esperion Therapeutics Inc (NASDAQ:ESPR) moving in opposite directions fo

The stock of Esperion Therapeutics Inc. ESPR, -0.31% slumped 22% in premarket trade Monday, as investors seemed to question whether data from a major study of its cholesterol-lowering drug Nexletol sh

Esperion Therapeutics, Inc. (NASDAQ:ESPR ) Q4 2022 Earnings Conference Call February 21, 2023 8:00 AM ET Company Participants Tiffany Aldrich - Associate Director, Corporate Communications Sheldon Koe

Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 12.64% and 5.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock

ANN ARBOR, Mich., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report fourth quarter and full year 2022 financial results before the open of the U.S. financial mar